oxcarbazepine

(redirected from Oxtellar XR)
Also found in: Medical.
Related to Oxtellar XR: Trokendi XR
Translations

oxcarbazepine

n oxcarbazepina
References in periodicals archive ?
M2 EQUITYBITES-June 23, 2016-Supernus awarded seventh US patent protecting its antiepileptic drug Oxtellar XR
Supernus awarded seventh US patent protecting its antiepileptic drug Oxtellar XR
M2 PHARMA-June 2, 2016-Supernus awarded sixth US patent for antiepileptic drug Oxtellar XR
Supernus awarded sixth US patent for antiepileptic drug Oxtellar XR
M2 EQUITYBITES-June 2, 2016-Supernus awarded sixth US patent for antiepileptic drug Oxtellar XR
Supernus awarded sixth US patent for antiepileptic drug Oxtellar XR
M2 PHARMA-September 3, 2015-Supernus wins fifth US patent for antiepileptic drug Oxtellar XR
Supernus wins fifth US patent for antiepileptic drug Oxtellar XR
It has two marketed products for epilepsy, Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate).
Supernus reports distribution of 3,820,625 common stock through NEA
Additionally, Supernus Pharmaceuticals has two marketed products for epilepsy, Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate).
Supernus updates distribution of its common stock
M2 EQUITYBITES-September 3, 2015-Supernus wins fifth US patent for antiepileptic drug Oxtellar XR
Supernus wins fifth US patent for antiepileptic drug Oxtellar XR
M2 PHARMA-September 5, 2014-Supernus wins fourth US patent for Oxtellar XR for the treatment of epilepsy
Supernus wins fourth US patent for Oxtellar XR for the treatment of epilepsy
M2 PHARMA-January 8, 2014-Supernus Pharmaceuticals Inc wins third US patent for Oxtellar XR for the treatment of epilepsy
Supernus Pharmaceuticals Inc wins third US patent for Oxtellar XR for the treatment of epilepsy
M2 EQUITYBITES-September 5, 2014-Supernus wins fourth US patent for Oxtellar XR for the treatment of epilepsy
Supernus wins fourth US patent for Oxtellar XR for the treatment of epilepsy
Specialist pharmaceutical company Supernus Pharmaceuticals Inc (NasdaqGM:SUPN) said on Monday that the US Food and Drug Administration (FDA) has granted the company's Oxtellar XR with three years of market exclusivity.
Supernus Pharmaceuticals Inc awarded three years of market exclusivity for partial seizures drug, Oxtellar XR
M2 EQUITYBITES-January 8, 2014-Supernus Pharmaceuticals Inc wins third US patent for Oxtellar XR for the treatment of epilepsy
Supernus Pharmaceuticals Inc wins third US patent for Oxtellar XR for the treatment of epilepsy
Dictionary browser ?
Full browser ?